Valneva (NASDAQ:VALN) Shares Up 6.1%

Valneva SE (NASDAQ:VALN)’s share price shot up 6.1% on Thursday . The company traded as high as $8.22 and last traded at $8.22. 1,859 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 9,146 shares. The stock had previously closed at $7.75.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on VALN. HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Valneva in a report on Thursday, March 21st. Guggenheim lowered their price target on shares of Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a report on Friday, March 22nd.

Valneva Price Performance

The business’s fifty day simple moving average is $7.67 and its 200 day simple moving average is $9.62. The company has a current ratio of 1.65, a quick ratio of 1.37 and a debt-to-equity ratio of 1.04.

Valneva (NASDAQ:VALN) last released its earnings results on Wednesday, March 20th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.70). Valneva had a negative return on equity of 59.48% and a negative net margin of 65.99%. The business had revenue of $45.12 million for the quarter, compared to analyst estimates of $45.06 million. Equities analysts expect that Valneva SE will post 0.11 EPS for the current year.

Institutional Trading of Valneva

A number of institutional investors have recently bought and sold shares of VALN. UBS Group AG acquired a new stake in Valneva during the 2nd quarter worth $31,000. Jane Street Group LLC grew its holdings in shares of Valneva by 85.9% in the 1st quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock valued at $569,000 after buying an additional 7,664 shares during the period. Finally, Bank of America Corp DE acquired a new position in shares of Valneva in the 1st quarter valued at $858,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.